Taltz® (Ixekizumab)

Para consultar la información para prescribir completa de Taltz® (Ixekizumab) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Ixekizumab: Comparison With Tildrakizumab in Psoriasis

No head-to-head data comparing ixekizumab with tildrakizumab are available. Indirect comparison analyses are provided below.

MX_cFAQ_IXE442_COMPARISON_TILDRAKIZUMAB_PsO
MX_cFAQ_IXE442_COMPARISON_TILDRAKIZUMAB_PsO
es-MX

Detailed Information

The information contained in this letter may not completely match the current local labeling for IXEKIZUMAB. Please see local labeling approved in your country. 

Ixekizumab is a humanized IgG4 mAb that selectively binds with the IL-17A cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.1

No head-to-head trials have been conducted comparing the efficacy and safety of ixekizumab to that of tildrakizumab in the treatment of psoriasis.

Since clinical trials are conducted under widely varying and controlled conditions, efficacy outcomes and adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Tildrakizumab-asmn is a humanized IgG1/k mAb that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.2

Adjusted Indirect Comparison of Ixekizumab and Tildrakizumab in Plaque Psoriasis

The methodology used to indirectly compare the efficacy outcomes (PASI 75, PASI 90, and PASI 100) of ixekizumab and tildrakizumab in patients with moderate-to-severe psoriasis were

  • AIC using the Bucher method, and
  • MAIC using the Signorovitch method in which reweighting was performed matching the following baseline characteristics in terms of means or percentages: patient age, sex, previous biologic treatment, PASI score, and BSA affected.3

Both methods of indirect comparisons used are subject to limitations including the potential for bias due to differences between trial populations and imbalances in unobserved factors between trials. These limitations can only be avoided with head-to-head randomized trials.4,5

As shown in Study Design for Indirect Comparison of Ixekizumab and Tildrakizumab, etanercept and placebo were used as the common comparators for the indirect comparison of ixekizumab and tildrakizumab.3

Study Design for Indirect Comparison of Ixekizumab and Tildrakizumab3

Abbreviations: ETN = etanercept; IXE = ixekizumab; PASI 75/90/100 = 75%/90%/100% improvement from baseline in Psoriasis Area and Severity Index; PBO = placebo; TIL = tildrakizumab.

Dashed line represents indirect comparison and solid line represents direct comparison.

The risk differences for PASI responses up to week 12 are available in Ixekizumab vs Tildrakizumab Indirect Comparison of PASI Responses Via Comparator Bridges.

The authors concluded the results of this indirect comparison suggest that ixekizumab might provide clinical benefits over tildrakizumab in terms of faster onset of action and higher levels of skin clearance up to week 12 in patients with moderate-to-severe psoriasis.3

Ixekizumab vs Tildrakizumab Indirect Comparison of PASI Responses Via Comparator Bridges3

Abbreviations: AIC = adjusted indirect comparison; ETN = etanercept; IXE = ixekizumab; MAIC = matching adjusted indirect comparison; PASI = Psoriasis Area Severity Index; PASI 75/90/100 = 75%/90%/100% improvement from baseline in Psoriasis Area and Severity Index; PBO = placebo; TIL = tildrakizumab.

References

1Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

2ILUMYA [package insert]. Sharjah, U.A.E.: Sun Pharma Global FZE, Inc; 2018.

3Gottlieb A, Saure D, Wilhelm S, et al. Indirect comparison of ixekizumab versus tildrakizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis. Poster presented at: 77th Annual Meeting of the American Academy of Dermatology; March 1-5, 2019; Washington, D.C. https://www.aad.org/eposters/Submissions/getFile.aspx?id=8051&type=sub

4Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50(6):683-691. https://doi.org/10.1016/S0895-4356(97)00049-8

5Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935-945. http://dx.doi.org/10.2165/11538370-000000000-00000

Glossary

AIC = adjusted indirect comparison

BSA = body surface area

IgG1 = immunoglobulin G subclass 1

IgG4 = immunoglobulin G subclass 4

IL = interleukin

mAb(s) = monoclonal antibody

MAIC = matched-adjusted indirect comparison

PASI = Psoriasis Area and Severity Index

PASI 75 = 75% improvement from baseline in Psoriasis Area and Severity Index

PASI 90 = 90% improvement from baseline in Psoriasis Area and Severity Index

PASI 100 = 100% improvement from baseline in Psoriasis Area and Severity Index

Fecha de la última revisión: 2019 M08 19


Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta